News brief
On 2026-04-27, according to Xiniu Data, iRegene completed Series C financing, raising RMB 210 million. Investors were co-lead investor Nantongheyuanyihao Venture Capital Partnership (Limited Partnership), co-lead investor Xingze Capital. The company is a developer of chemically induced cell therapy drugs.
Connected profiles
Explore
Sources · 0Sources & provenance
English text is maintained separately from the original record. Consult the original source before citing a fact.
No source links are available for this profile.
Original source text
Names may use phonetic renderings when no English name is supplied. The original wording is retained below.
2026年4月27日，据烯牛数据报道，睿健医药完成C轮融资，金额2.10亿人民币。投资方为南通合远壹号创业投资合伙企业（有限合伙）、杏泽资本领投。该公司为化学诱导细胞治疗药物研发商。